Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial ...

A new study published in Sports Medicine and Health Science suggests that defecation may improve cognitive performance in ...

Inositol supplements show significant benefits for hormonal disorders, insulin sensitivity, and fertility issues, offering a ...

Researchers concluded that short, frequent bouts of exercise are best when it comes to lowering blood sugar levels, which in ...

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appo ...

Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly predicts Alzheimer's risk and progression.

Investing.com -- Shares of vTv Therapeutics Inc . (NASDAQ: VTVT) rose 15% after the company announced that the FDA has lifted the clinical hold on its Cadisegliatin program for diabetes. Trading had ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetesCATT1 Phase 3 trial expected to resume following ...